Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.62 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.54 |
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23390079 | 1.00 | HTR2C (0.68) | HTR2CEPHX1EPHX2LIPEMAPT | |
| SCHEMBL23390173 | 0.92 | HTR2C (0.59) | HTR2CEPHX1EPHX2LIPEMAPT | |
| SCHEMBL18960368 | 0.82 | EPHX2 (0.64) | EPHX1EPHX2LIPEMAPTTP53 | |
| SCHEMBL2146682 | 0.80 | KMT2A (0.56) | NPC1TSHRKMT2A | |
| SCHEMBL2146675 | 0.80 | KMT2A (0.56) | NPC1TSHRKMT2A | |
| SCHEMBL27852403 | 0.80 | EPHX1 (0.62) | HTR2CEPHX1EPHX2MAPTMEN1 | |
| SCHEMBL4630575 | 0.80 | HTR2C (0.62) | HTR2CEPHX1EPHX2LIPESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2146077 | 0.79 | KMT2A (0.55) | NPC1TSHRKMT2A | |
| Hydrochloric Acid SCHEMBL2146071 | 0.79 | KMT2A (0.55) | NPC1TSHRKMT2A | |
| SCHEMBL4630807 | 0.79 | HTR2C (0.61) | HTR2CEPHX1SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2017-06-15 | — | — | US | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166563-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | ALOX5, ALOX15, ALOX12 | HTR2C 149/4885EPHX1 65/4885EPHX2 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.